Come si colloca il rapporto CSL di PE rispetto ai suoi colleghi?

CSL ha un buon valore in base al suo rapporto Price-To-Earnings ( 32.2 x) rispetto alla media dei peer ( 56.9 x).

Come si colloca il CSL's PE Ratio rispetto ad altre aziende del Global Biotechs settore?

CSL è costoso in base al suo rapporto Price-To-Earnings ( 32.2 x) rispetto alla media del settore Global Biotechs ( 26.3 x).

Qual è il CSL PE Ratio rispetto al suo Fair PE Ratio? Si tratta del PE Ratio atteso, tenendo conto delle previsioni di crescita degli utili, dei margini di profitto e di altri fattori di rischio della società.

CSL è costoso in base al suo rapporto Price-To-Earnings ( 32.2 x) rispetto al rapporto equo Price-To-Earnings stimato ( 31.9 x).

Qual è il prezzo equo di CSL se si considerano i suoi flussi di cassa futuri? Per questa stima utilizziamo un modello di Discounted Cash Flow.

CSL ( A$272.45 ) viene scambiato al di sotto della nostra stima del [[fair value]] ( A$408.13 )

Qual è la previsione a 12 mesi degli analisti e abbiamo una qualche fiducia statistica nell'obiettivo di prezzo del consenso?

Il prezzo obiettivo è superiore di oltre 20 % rispetto al prezzo attuale delle azioni e gli analisti rientrano in un intervallo di accordo statisticamente attendibile.

CSL (ASX:CSL) - Prezzo delle azioni, notizie e analisi

CSL Panoramica delle azioni

CSL analisi fondamentale
Punteggio fiocco di neve
Valutazione	4/6
Crescita futura	3/6
Prestazioni passate	5/6
Salute finanziaria	4/6
Dividendi	4/6

Premi

Negoziato a 33.2% al di sotto della nostra stima del suo valore equo

Si prevede che gli utili cresceranno del 13% all'anno

Gli utili sono cresciuti del 20.4% nell'ultimo anno

Gli analisti concordano sul fatto che il prezzo delle azioni salirà di 20.3%

Analisi del rischio

Ha un alto livello di debito

CSL Limited Concorrenti

Telix Pharmaceuticals

ASX:TLX

AU$7.6b

Clinuvel Pharmaceuticals

ASX:CUV

AU$677.8m

Regeneron Pharmaceuticals

NasdaqGS:REGN

US$81.4b

Amgen

NasdaqGS:AMGN

US$152.4b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per CSL
Prezzi storici delle azioni
Prezzo attuale dell'azione	AU$272.45
Massimo di 52 settimane	AU$313.55
Minimo di 52 settimane	AU$255.17
Beta	0.30
1Variazione di 1 mese	-9.36%
Variazione a 3 mesi	-11.61%
Variazione di 1 anno	5.76%
3Variazione a 3 anni	-13.80%
Variazione a 5 anni	-0.35%
Variazione dall'IPO	33,956.59%

Notizie e aggiornamenti recenti

With EPS Growth And More, CSL (ASX:CSL) Makes An Interesting Case

Nov 01

We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt

Oct 05

CSL (ASX:CSL) Gains Approval for Updated COVID-19 Vaccine in Japan, Boosting Strategic Alliances

Sep 18

Recent updates

With EPS Growth And More, CSL (ASX:CSL) Makes An Interesting Case

Nov 01

We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt

Oct 05

CSL (ASX:CSL) Gains Approval for Updated COVID-19 Vaccine in Japan, Boosting Strategic Alliances

Sep 18

Getting In Cheap On CSL Limited (ASX:CSL) Is Unlikely

Sep 03

CSL Limited (ASX:CSL) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Aug 16

An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 27% Undervalued

Aug 07

CSL Limited's (ASX:CSL) Price Is Out Of Tune With Earnings

May 22

An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 20% Undervalued

May 01

CSL Limited's (ASX:CSL) Intrinsic Value Is Potentially 47% Above Its Share Price

Aug 13

CSL (ASX:CSL) Has A Pretty Healthy Balance Sheet

May 30

A Look At The Intrinsic Value Of CSL Limited (ASX:CSL)

May 09

Does CSL (ASX:CSL) Have A Healthy Balance Sheet?

Mar 01

Estimating The Fair Value Of CSL Limited (ASX:CSL)

Feb 07

CSL (ASX:CSL) Seems To Use Debt Quite Sensibly

Nov 17

CSL Limited (ASX:CSL) Shares Could Be 24% Below Their Intrinsic Value Estimate

Oct 27

We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt

Aug 19

Is CSL Limited (ASX:CSL) Trading At A 22% Discount?

Jul 29

CSL's (ASX:CSL) Problems Go Beyond Weak Profit

Feb 22

Rendimenti per gli azionisti

	CSL	AU Biotechs	AU Mercato
7D	-5.2%	-2.6%	-0.07%
1Y	5.8%	11.2%	16.9%

Ritorno vs Industria: CSL ha avuto una performance inferiore rispetto al Australian Biotechs che ha registrato un rendimento 11.2 % nell'ultimo anno.

Rendimento vs Mercato: CSL ha avuto una performance inferiore al mercato Australian che ha registrato un rendimento 16.9 % nell'ultimo anno.

Volatilità dei prezzi

Is CSL's price volatile compared to industry and market?
CSL volatility
CSL Average Weekly Movement	2.0%
Biotechs Industry Average Movement	10.1%
Market Average Movement	8.5%
10% most volatile stocks in AU Market	17.0%
10% least volatile stocks in AU Market	3.4%

Prezzo delle azioni stabile: CSL non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 2% ) di CSL è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1916	32,698	Paul McKenzie	www.csl.com.au

CSL Limited ricerca, sviluppa, produce, commercializza e distribuisce biofarmaci e vaccini in Australia, Stati Uniti, Germania, Regno Unito, Svizzera, Cina, Hong Kong e a livello internazionale. L'azienda opera attraverso i segmenti CSL Behring, CSL Seqirus e CSL Vifor. Il segmento CSL Behring offre prodotti a base di plasma, terapie geniche e ricombinanti.

CSL Limited Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di CSL con la sua capitalizzazione di mercato?
CSL statistiche fondamentali
Capitalizzazione di mercato	AU$131.92b
Guadagni(TTM)	AU$4.09b
Ricavi(TTM)	AU$22.92b

32.2x

Rapporto P/E

5.8x

Rapporto P/S

CSL è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
CSL Conto economico (TTM)
Ricavi	US$14.80b
Costo del fatturato	US$7.10b
Profitto lordo	US$7.71b
Altre spese	US$5.06b
Guadagni	US$2.64b

Ultimi guadagni dichiarati

Jun 30, 2024

Prossima data di guadagno

Feb 10, 2025

Utile per azione (EPS)	5.46
Margine lordo	52.06%
Margine di profitto netto	17.85%
Rapporto debito/patrimonio netto	54.2%

Come si è comportato CSL nel lungo periodo?

Vedi performance storica e confronto

Dividendi

1.5%

Rendimento attuale del dividendo

48%

Rapporto di remunerazione

CSL Panoramica delle azioni

Premi

Analisi del rischio

CSL Limited Concorrenti

ASX:TLX

AU$7.6b

ASX:CUV

AU$677.8m

NasdaqGS:REGN

US$81.4b

NasdaqGS:AMGN

US$152.4b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

MD, CEO & Executive Director recently sold AU$1.1m worth of stock

With EPS Growth And More, CSL (ASX:CSL) Makes An Interesting Case

CSL Vifor and Travere Therapeutics Announces Swissmedic Approval of FILSPARI (Sparsentan) for the Treatment of IgA Nephropathy

We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt

CSL (ASX:CSL) Gains Approval for Updated COVID-19 Vaccine in Japan, Boosting Strategic Alliances

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics Holdings Inc.'s Updated Self-Amplifying mRNA Covid-19 Vaccine for Protection Against JN.1 Strain

Recent updates

MD, CEO & Executive Director recently sold AU$1.1m worth of stock

With EPS Growth And More, CSL (ASX:CSL) Makes An Interesting Case

CSL Vifor and Travere Therapeutics Announces Swissmedic Approval of FILSPARI (Sparsentan) for the Treatment of IgA Nephropathy

We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt

CSL (ASX:CSL) Gains Approval for Updated COVID-19 Vaccine in Japan, Boosting Strategic Alliances

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics Holdings Inc.'s Updated Self-Amplifying mRNA Covid-19 Vaccine for Protection Against JN.1 Strain

MD, CEO & Executive Director exercised options and sold AU$1.1m worth of stock

Getting In Cheap On CSL Limited (ASX:CSL) Is Unlikely

Upcoming dividend of US$1.45 per share

CSL Limited (ASX:CSL) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Final dividend of US$1.45 announced

Full year 2024 earnings: EPS misses analyst expectations

CSL Limited to Report First Half, 2025 Results on Feb 11, 2025

An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 27% Undervalued

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine

CSL Limited's (ASX:CSL) Price Is Out Of Tune With Earnings

An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 20% Undervalued

Now 21% undervalued after recent price drop

CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

Does CSL (ASX:CSL) Have A Healthy Balance Sheet?

Now 20% undervalued

CSL Seqirus Confirms Full Preparation to Implement the Fda's Vaccines and Related Biological Products Advisory Committee

Upcoming dividend of US$1.19 per share

First half dividend of US$1.19 announced

First half 2024 earnings: EPS misses analyst expectations

CSL Limited Announces Estimate Distribution for the Six Months Ended December 31, 2023, Payable on April 3, 2024

CSL Announces Top-Line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I (Human)

Now 22% undervalued

CSL Limited's (ASX:CSL) Earnings Haven't Escaped The Attention Of Investors

Now 21% undervalued

CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicronba BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster Booster

CSL Limited to Report Fiscal Year 2024 Results on Jul 30, 2024

CSL Behring's HEMGENIX (Etranacogene Dezaparvovec-Drlb) Demonstrates At Three Years Post-T Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B

Is CSL (ASX:CSL) Using Too Much Debt?

Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the First Self-Amplifying mRNA Vaccine Approves for COVID in Adults

CSL Limited (ASX:CSL) Shares Could Be 28% Below Their Intrinsic Value Estimate

Health Canada Authorizes Csl's Hemgenix(R) (Etranacogene Dezaparvovec) as First Gene Therapy for Hemophilia B

CSL Limited Reaffirms Financial Outlook for Fiscal Year 2024

CSL Seqirus Announces Data from Three Studies Supporting the Clinical, Public Health Benefit and Cost Savings Associated with Cell-Based and Adjuvanted Influenza Vaccines

CSL Seqirus Shares Data Demonstrating the Potential for Influenza Vaccination to Reduce the Burden on Healthcare Resources

These 4 Measures Indicate That CSL (ASX:CSL) Is Using Debt Reasonably Well

Arcturus Therapeutics Holdings Inc. and Csl Seqirus Announce European Medicines Agency Validates Marketing Authorization Application for Arct-154 Vaccine to Prevent Covid-19

Upcoming dividend of US$1.29 per share at 1.4% yield

Independent Non-Executive Chairman recently sold AU$5.6m worth of stock

CSL Appoints Jeffrey Ball as First Chief Sustainability Officer

CSL Limited, Annual General Meeting, Oct 09, 2024

Full year 2023 earnings: EPS misses analyst expectations

CSL Limited's (ASX:CSL) Intrinsic Value Is Potentially 47% Above Its Share Price

CSL Limited to Report Fiscal Year 2023 Results on Aug 15, 2023

CSL (ASX:CSL) Has A Pretty Healthy Balance Sheet

A Look At The Intrinsic Value Of CSL Limited (ASX:CSL)

Upcoming dividend of US$1.07 per share at 1.1% yield

Does CSL (ASX:CSL) Have A Healthy Balance Sheet?

First half 2023 earnings released: EPS: US$3.37 (vs US$3.85 in 1H 2022)

CSL Limited Announces Interim Dividend, Payable on 5 April 2023

Estimating The Fair Value Of CSL Limited (ASX:CSL)

CSL Limited, Annual General Meeting, Oct 11, 2023

CSL Limited to Report First Half, 2023 Results on Feb 14, 2023

SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases